MET receptor sequence variants R970C and T992I lack transforming capacity. - Wikidata - awgldk - TriplyDB

MET receptor sequence variants R970C and T992I lack transforming capacity.

MET receptor sequence variants R970C and T992I lack transforming capacity.

http://www.wikidata.org/entity/Q34033952

about

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance Biology of MET: a double life between normal tissue repair and tumor progression Activating mutation in MET oncogene in familial colorectal cancer.The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.Prospective enterprise-level molecular genotyping of a cohort of cancer patients.Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines Functional consequence of the MET-T1010I polymorphism in breast cancer Retrospective Review of MET Gene Mutations.Autism Linked to Increased Oncogene Mutations but Decreased Cancer Rate.Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia.SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer.A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.Targeting the HGF/Met signaling pathway in cancer therapy Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.Genetically informed lung cancer medicine.c-MET as a potential therapeutic target and biomarker in cancer.Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?MET and Small-Cell Lung Cancer.cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.MET T992I mutation in a case of ependymoblastoma/embryonal tumour with multilayered rosettes.Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients.

P2860

Q26799900-56E5EEA6-89D9-426A-B6B5-0F6E56BD28B1 Q28085247-43FAB75F-8189-4F77-957A-EBDB0F2169E9 Q34039577-7B1E82AB-FA1E-426D-B79C-D15547E15B38 Q34141913-72E80614-603A-47D1-8F1A-97B6597E712D Q34402363-90B666C1-68BD-4004-BFC6-FB643E239457 Q34409739-A581C242-2764-498D-9DBC-209E56E6F89A Q35169273-83C0D50E-D22A-482A-B873-526A02B46BC9 Q35208173-70961B7C-5957-4506-8D6C-7CB62208C69B Q35550045-6538091E-5969-448B-A74C-29747019320E Q35745037-55AB697E-9788-4FA3-A362-4DA3E2EEA2C6 Q35943062-AC64FF5E-1C49-4D76-8E6C-EB725721EEB0 Q36263622-F8453634-1552-4F72-842F-3599CB8A3302 Q36346565-59C1D642-91C9-4E39-9CC2-37CFE3F8B2AF Q36608758-3265CE05-49ED-437B-926A-CFA6906488B5 Q37013777-80CCE388-CC66-4DD2-9291-3FC84546A844 Q37406889-FE147835-B9D5-4B63-888E-6B5A658FA47E Q37651008-9F762ABA-3CF7-42B7-BE88-7DF91DE226D8 Q37706900-46223500-2F26-4AE2-8A7A-8866F2287C2D Q37815136-BA1E6A81-63A2-45D7-9DCC-5D02A3CCC25A Q37962905-D9F7E075-1B4F-480B-89C1-51836596B613 Q38150768-31C53F2C-1568-4B5E-B6C3-FEFB779D2039 Q38239580-7EE0D586-263C-4AC7-8554-55EC115D31A0 Q38260120-BDF5C0F0-78C3-4464-94AC-C1C329B95DE9 Q38393333-484C36A8-AAFB-4F5B-B1FA-8BC9D4617B5E Q38735120-0520FE96-D83C-4FB4-84E4-EC70BBB5AEA7 Q39449489-EE6DF115-570E-428C-B7D9-4998CEE486B3 Q41636404-843DA0BD-CCB1-4133-A00A-2F52E49274AA Q46836891-A086D3D7-FAEB-44F2-967E-1FECA071D327 Q47400935-CB7CA263-E44C-44FE-9884-0D52FD376DF1 Q48561269-5FD3D951-8D1A-4E26-A555-6C6286C7AD02 Q50351356-86FE9260-C61F-420E-8D23-9DC53E267400 Q52312700-B7F78108-91F6-49BA-B6E1-B066C148C930 Q55070113-03B6F619-8C02-47A4-9298-F74C9A147115

P2860

MET receptor sequence variants R970C and T992I lack transforming capacity.

http://www.wikidata.org/entity/Q34033952

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

MET receptor sequence variants R970C and T992I lack transforming capacity.

@ast

MET receptor sequence variants R970C and T992I lack transforming capacity.

@en

MET receptor sequence variants R970C and T992I lack transforming capacity.

@nl

type

label

MET receptor sequence variants R970C and T992I lack transforming capacity.

@ast

MET receptor sequence variants R970C and T992I lack transforming capacity.

@en

MET receptor sequence variants R970C and T992I lack transforming capacity.

@nl

prefLabel

MET receptor sequence variants R970C and T992I lack transforming capacity.

@ast

MET receptor sequence variants R970C and T992I lack transforming capacity.

@en

MET receptor sequence variants R970C and T992I lack transforming capacity.

@nl

P1433

Q34033952-64534E76-EE91-41B3-9A8F-F75F7EA7C6B7

P1476

Q34033952-7C3E9AED-0187-4DF6-8369-153DB86AA45B

P2093

Q34033952-0A512F3A-D471-448E-810D-19D519A13902

Q34033952-331AB2F1-BA26-473E-9C9D-60B580524317

Q34033952-3905F238-8524-4A98-8270-72CA0026B767

Q34033952-8B37F72D-C234-4D5D-80A6-CF26A04A0025

Q34033952-C12950AF-B83C-45E0-AE30-4D56BB5E8589

Q34033952-C19BD33E-EF49-4A7D-B044-E00B1D9AD159

Q34033952-CE04F8AB-1AD4-4A6A-AAD9-D65AFED46F4C

Q34033952-D0D32DAD-915C-48FA-9D74-4CE64EF00081

P2860

Q34033952-0442EDBF-8166-44B7-BCE5-E992428A6827

Q34033952-0C4C51F7-3094-4C66-941B-26EECCBCB20B

Q34033952-0FF80204-8C5E-4A73-9B22-1817248AA6FD

Q34033952-2AE3E03F-A833-4769-8B6D-E39C158C2943

Q34033952-4358A0F5-8722-45CA-B475-3E24A3C453F0

Q34033952-49B95534-0BC1-495E-981F-28E66D680481

Q34033952-57BF0118-3671-46B3-B1B1-0A9E969EF495

Q34033952-59F2C9DA-E873-43DA-9C9D-79E6D55CB49E

Q34033952-68EC099E-D3B4-4B27-9974-DB8D92DA34C9

Q34033952-6C6E0E4F-11A7-4747-9401-8C4DBE2B4733

P304

Q34033952-33CD14E8-06BC-45B6-A8FA-518948B41E52

P31

Q34033952-2831D084-A755-4622-8AFB-7E94A5E30CBE

P356

Q34033952-4AD87255-D3AC-42CB-843D-8F2E6636AB4D

P407

Q34033952-7469B659-41B3-43E4-9356-E9D4261DF0A9

P433

Q34033952-D05E3143-3B94-4FA7-A342-84FD962F0AD4

P478

Q34033952-F555A01D-AE4B-418F-B560-C27E1D922E97

P50

Q34033952-31703A38-D715-499F-A4B6-660D1C0A88B5

Q34033952-60AB4998-063B-461D-9F0E-DBE7A52A6C6B

Q34033952-69FFBC69-E6F5-487C-8D03-D9F27BF7C24A

P577

Q34033952-17C2B9E3-2166-478C-A05D-5AF0C3EC358B

P698

Q34033952-D308BC15-690F-4B3E-828A-0E3BA28C088A

P932

Q34033952-B20E1ECF-DD5A-4222-AEAF-FE37992262E8

P356

0008-5472.CAN-10-0429

P1433

Cancer Research

P1476

MET receptor sequence variants R970C and T992I lack transforming capacity.

@en

P2093

Carol Beadling

http://www.w3.org/2001/XMLSchema#string

Ellen Q Wang

http://www.w3.org/2001/XMLSchema#string

Luke B Fletcher

http://www.w3.org/2001/XMLSchema#string

Marc M Loriaux

http://www.w3.org/2001/XMLSchema#string

Michael L Rutenberg-Schoenberg

http://www.w3.org/2001/XMLSchema#string

Michael W Deininger

http://www.w3.org/2001/XMLSchema#string

Motomi Mori

http://www.w3.org/2001/XMLSchema#string

Wayne F Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing.

High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.

Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

Activating mutations for the met tyrosine kinase receptor in human cancer.

P304

6233-6237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-0429

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Brian J. Druker

Michael C. Heinrich

Jeffrey W. Tyner

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20670955

http://www.w3.org/2001/XMLSchema#string

P932

2913476

http://www.w3.org/2001/XMLSchema#string